Related Experiment Video
Updated: Jul 12, 2025
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Transplant Vasculopathy Versus Native Atherosclerosis: Similarities and Differences
1Department of Internal Medicine I, Krankenhaus Neuwittelsbach, Munich, Germany.
Insights
Cardiac allograft vasculopathy (CAV) is a major cause of heart transplant failure, characterized by rapid arterial disease. Early diagnosis and effective treatments for CAV remain challenging, impacting patient survival.
Area of Science:
- Cardiology
- Immunology
- Transplantation
Background:
- Cardiac allograft vasculopathy (CAV) is a primary driver of graft failure and mortality post-heart transplantation.
- Pathogenesis involves alloimmune and non-alloimmune factors activating recipient and donor immune systems.
- Early CAV diagnosis is difficult due to denervated heart ischemia, functional changes, insensitive angiography, and microvascular involvement.
Purpose of the Study:
- To elucidate the characteristics and challenges in diagnosing and managing Cardiac Allograft Vasculopathy (CAV).
- To differentiate CAV from native coronary atherosclerosis.
- To highlight the poor prognosis and limited treatment efficacy for CAV.
Main Methods:
- Review of existing literature on CAV pathogenesis, diagnosis, and comparison with native atherosclerosis.
- Analysis of clinical presentation and outcomes in heart transplant recipients versus native heart patients.
Main Results:
- CAV is a panarterial disease within the allograft, featuring intimal hyperplasia and medial disease.
- CAV plaque composition varies from fibrous to calcified, differing from focal native atherosclerosis.
- Heart transplant recipients with acute coronary syndromes face higher mortality and cardiogenic shock risk.
Conclusions:
- CAV presents unique diagnostic and therapeutic challenges compared to native coronary artery disease.
- The rapid, diffuse nature of CAV and its poor prognosis necessitate improved management strategies.
- Effective prevention and treatment strategies for CAV are urgently needed to improve long-term outcomes in heart transplant recipients.
Abstract:
Cardiac allograft vasculopathy (CAV) is one of the leading causes of graft failure and death after heart transplantation. Alloimmune-dependent and -independent factors trigger the pathogenesis of CAV through activation of the recipients' (and to a lesser extent donor-derived) immune system. Early diagnosis of CAV is complicated by the lack of clinical symptoms for ischemia in the denervated heart, by the impact of early functional coronary alterations, by the insensitivity of coronary angiography, and by the involvement of small intramyocardial vessels. CAV in general is a panarterial disease confined to the allograft and characterized by diffuse concentric longitudinal intimal hyperplasia in the epicardial coronary arteries and concentric medial disease in the microvasculature. Plaque composition in CAV may include early fibrous and fibrofatty tissue and late atheromatous calcification. In contrast, native coronary atherosclerosis usually develops over decades, is focal, noncircumferential, and typically diminishes proximal parts of the epicardial vessels. The rapid and early development of CAV has an adverse prognostic impact, and current prevention and treatment strategies are of limited efficacy compared with established strategies in native atherosclerosis. Following acute coronary syndromes, patients after heart transplantation were more likely to have accompanying cardiogenic shock and higher mortality compared with acute coronary syndromes patients with native hearts.
Related Concept Videos
01:30Atherosclerosis I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
01:20Overview of the Vascular System
01:15Structure of Blood Vessels
01:23Atherosclerosis IV: Nursing Management